株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の禁煙およびニコチン依存症治療製品市場:タイプ・地域別 - 成長、動向、予測(2018年〜2023年)

Global Smoking Cessation and Nicotine De-Addiction Products Market - by Type and Geography - Growth, Trends, and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 661178
出版日 ページ情報 英文 109 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=112.86円で換算しております。
Back to Top
世界の禁煙およびニコチン依存症治療製品市場:タイプ・地域別 - 成長、動向、予測(2018年〜2023年) Global Smoking Cessation and Nicotine De-Addiction Products Market - by Type and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日: 2018年05月21日 ページ情報: 英文 109 Pages
概要

世界の禁煙およびニコチン依存症治療製品市場の2018年から2023年のCAGR(複合年間成長率)は約14%になると予測されています。喫煙は肺癌をはじめ、呼吸器疾患や心臓病の主な原因のひとつとされています。

当レポートでは、世界の禁煙およびニコチン依存症治療製品市場を調査し、市場の概要、タイプ・地域別の市場規模の推移と予測、市場動向、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、市場機会、課題

  • 市場の成長要因
    • 喫煙の健康被害と禁煙治療の認知度の上昇
    • 新製品の登場
    • 禁煙治療に対する償還制度
  • 市場の阻害要因
    • 途上国における禁煙製品の認知度の低さ
    • 生活ストレスに誘因される喫煙
    • 禁煙製品セグメントの成長の足かせとなっている法規制
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • タイプ別
    • ニコチン置換療法
    • 禁煙・ニコチン依存症治療製品
    • 電子タバコ
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Imperial Tobacco Company of India Limited.
  • McNeil AB
  • NJOY, Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Revolymer PLC
  • 武田薬品工業
  • その他の企業

第10章 市場の将来展望

目次
Product Code: 52663

The global smoking cessation and nicotine de-addiction products market is expected to register a CAGR of about 14% during the forecast period, 2018-2023. Smoking is one of the major causes of lung cancer and other respiratory and cardiac diseases. Awareness about these health hazards has influenced individuals to adopt smoking cessation therapy. Awareness digital media, print media, and other sources of information have proved to be effective in curbing the nicotine addiction crisis to some extent.

Lifestyle Related Issues Leading to Stress

Tobacco use is risky behavior among youth that extends into adulthood. Quitting smoking is beneficial to health at any age, and smokers who quit before 35 years of age have mortality rates similar to those who never smoked. Of the current 44.5 million smokers in the United States, 70% (31 M) claim they would like to quit, 70% of smokers visit a physician yearly, and 46% report an attempt to quit smoking in the past year, which leads to high usage of De-addiction products. Also, this portrays the rising awareness of the population and their willingness to quit smoking. The rise in awareness is also fueled by government efforts, such as advertisements, and distribution of educational pamphlets, etc. Also, there are non-government organizations working to educate and help people quit smoking are that are engaged dedicatedly to bring the number of smokers down. This will allow the smoking cessation and nicotine de-addiction products market to flourish during the forecast period. Other factors that will help the market to grow during the forecast period include introduction of new products and reimbursement for smoking cessation therapy.

Lifestyle Related Stress Triggering Smoking

Most adults say that they smoke because of habit or routine and/or because it helps them relax and cope with stress. Many smokers are more likely to increase their cigarette use when they're under pressure. Certain events, such as holidays, job changes, and life transitions, can trigger certain habits, including smoking. The idea that people smoke cigarettes to help ease the signs and symptoms of stress is known as 'self-medication'. Stress is very common, affecting us when we feel unable to cope with unwelcome pressure. It can cause physical symptoms, like headaches or breathlessness, as well as making people feel irritable, anxious or low. Owing to this more people are reluctant to quit smoking and with the addition of new smokers every day the growth of the smoking cessation and nicotine de-addiction products market will have a negative impact during the forecast period. Other factors that will act as restraints for the market include low awareness about smoking cessation products in developing economies and legal obligations dragging growth of several smoking cessation product segments.

Asia-Pacific to Show Fastest Growth

North America is expected to dominate the market during the forecast years, due to increasing number of smokers and growing awareness regarding health hazards associated with smoking. Asia-Pacific is expected to be the fastest growing region for the market, due to increasing awareness about the smoking cessation and nicotine de-addiction products and a huge population base in the area.

Key Developments in the Market:

  • December 2017 - US Food and Drug Administration announced an adult smoking cessation education campaign aimed at encouraging cigarette smokers to quit through messages of support that underscore the health benefits of quitting. These messages will be displayed in and around gas stations and convenience stores - retail locations where smokers face a multitude of triggers and that typically feature cigarette advertisements
  • Major Players: CIPLA LTD., GLAXOSMITHKLINE PLC, IMPERIAL TOBACCO COMPANY OF INDIA LIMITED., MCNEIL AB, NJOY, INC., NOVARTIS INTERNATIONAL AG, PFIZER, INC., REVOLYMER PLC AND TAKEDA PHARMACEUTICAL CO., LTD., amongst others.

Reasons to Purchase the Report:

  • Current and future smoking cessation and de-addiction products market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market with the help of Porter's five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report:

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Rising Awareness About Smoking Health Hazards And Smoking Cessation Therapy
    • 6.1.2 Introduction Of New Products
    • 6.1.3 Reimbursement For Smoking Cessation Therapy
  • 6.2 Market Restraints
    • 6.2.1 Low Awareness About Smoking Cessation Products In Developing Economies
    • 6.2.2 Lifestyle Related Stress Triggering Smoking
    • 6.2.3 Legal Obligations Dragging Growth Of Several Smoking Cessation Product Segments
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Type
    • 7.1.1 By Nicotine Replacement Therapies
      • 7.1.1.1 Nicotine Gums
      • 7.1.1.2 Nicotine Patches
      • 7.1.1.3 Nicotine Sprays
      • 7.1.1.4 Nicotine Inhalers
      • 7.1.1.5 Nicotine Lozenges
      • 7.1.1.6 Nicotine Sub lingual Tablets
    • 7.1.2 Smoking Cessation and Nicotine De-addiction Products
      • 7.1.2.1 Bupropione (Zyban)
      • 7.1.2.2 Global Varenicline (Champix, Chantix)
    • 7.1.3 E-cigarettes
  • 7.2 By Geography
    • 7.2.1 North America
      • 7.2.1.1 United States
      • 7.2.1.2 Canada
      • 7.2.1.3 Mexico
    • 7.2.2 Europe
      • 7.2.2.1 France
      • 7.2.2.2 Germany
      • 7.2.2.3 United kingdom
      • 7.2.2.4 Italy
      • 7.2.2.5 Spain
      • 7.2.2.6 Rest of Europe
    • 7.2.3 Asia-Pacific
      • 7.2.3.1 India
      • 7.2.3.2 Australia & New Zealand
      • 7.2.3.3 South korea
      • 7.2.3.4 Rest of Asia-Pacific
    • 7.2.4 Rest of World
      • 7.2.4.1 Saudi Arabia
      • 7.2.4.2 Brazil
      • 7.2.4.3 Others

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Cipla Ltd.
  • 9.2 GlaxoSmithKline plc
  • 9.3 Imperial Tobacco Company of India Limited.
  • 9.4 McNeil AB
  • 9.5 NJOY, Inc.
  • 9.6 Novartis International AG
  • 9.7 Pfizer, Inc.
  • 9.8 Revolymer PLC
  • 9.9 Takeda Pharmaceutical Co., Ltd.
  • 9.10 List Not Exhaustive

10. Future of the Market

Back to Top